Not available
Quote | BioLineRx Ltd. (NASDAQ:BLRX)
Last: | $0.85 |
---|---|
Change Percent: | -0.21% |
Open: | $0.8734 |
Close: | $0.85 |
High: | $0.89 |
Low: | $0.813 |
Volume: | 484,552 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | BioLineRx Ltd. (NASDAQ:BLRX)
2024-05-30 13:54:38 ET More on biolinerx BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on biolinerx Historical earnings data for biolinerx Financial in...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Message Board Posts | BioLineRx Ltd. (NASDAQ:BLRX)
Subject | By | Source | When |
---|---|---|---|
BioLineRx to Report First Quarter 2023 Results on | midastouch017 | investorshub | 05/17/2023 12:03:40 PM |
Philip Serlin: I would like to take a | midastouch017 | investorshub | 05/11/2023 5:17:14 PM |
1.6792+0.1692 (+11.2053%) | midastouch017 | investorshub | 05/11/2023 3:10:39 PM |
Lets go go go go... Up up and away we go. | midastouch017 | investorshub | 05/11/2023 2:03:17 PM |
Three out of four: Protlix also received marketing | midastouch017 | investorshub | 05/11/2023 12:48:56 PM |
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...